Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of methyllycaconitine or citrate thereof in prevention or treatment of HIV related neurocognitive dysfunction

A technology of methyl bovine citric acid and cognitive dysfunction, which is applied in the field of biomedicine, can solve the problem of HIV-1 concurrent HAND without any therapeutic effect, and achieve the reduction of brain tissue damage, improvement of inflammation and cell damage, Reduce the effect of transcription

Pending Publication Date: 2021-09-17
SOUTHERN MEDICAL UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Relevant documents show that the occurrence of HAND symptoms is closely related to a high concentration of plasma viral load. Although highly active antiretroviral therapy (HAART, ie cocktail therapy) has been widely used in the treatment of HIV-1 patients and has achieved significant results, but for HIV -1 HAND concurrently has no therapeutic effect. At present, there is no specific drug and treatment strategy that can effectively treat HAND clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methyllycaconitine or citrate thereof in prevention or treatment of HIV related neurocognitive dysfunction
  • Application of methyllycaconitine or citrate thereof in prevention or treatment of HIV related neurocognitive dysfunction
  • Application of methyllycaconitine or citrate thereof in prevention or treatment of HIV related neurocognitive dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043] In order to make the object, technical solution and technical effect of the present invention clearer, the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the specific implementations described in this specification are only for explaining the present invention, not for limiting the present invention.

[0044] The experimental materials and reagents used, unless otherwise specified, are conventional consumables and reagents that can be obtained from commercial channels.

[0045] Cytotoxicity test of methyl bovine citrate

[0046] In this example, in order to verify the cytotoxicity of methylcaconitine citrate (MLA), ASTR cells were treated with different concentrations (1nM-1000nM) of methylcaconitine citrate, and after incubation for 24h , to examine the viability of ASTR cells. Cells without methyl gentine citrate were used as a control.

[0047] Cell viability was detected by CCK8 (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of methyllycaconitine or citrate thereof in prevention or treatment of HIV related neurocognitive dysfunction. Wherein the use dosage of the methylethylenediamine or the pharmaceutically acceptable salt thereof is 1 nM to 1000 nM. The inventor finds that methyllycaconitine or citrate thereof can effectively inhibit alpha7nAChR activation, improve inflammation and cell injury induced by gp120, relieve brain tissue injury and improve cognitive disorder caused by HAND, so that the methyllycaconitine or citrate thereof has the effect of remarkably improving HAND symptoms concurrent by HIV, and a new target and a new way are provided for clinical treatment of HAND.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of methyl botanine or its citrate in the prevention or treatment of HIV-related neurocognitive dysfunction. Background technique [0002] HIV-1 is one of the most challenging infectious diseases facing mankind. In addition to causing acquired immunodeficiency syndrome (AIDS), HIV-1 infection can also lead to a series of systemic complications, such as chronic inflammation and HIV-associated neurocognitive dysfunction (HAND). Symptoms of HAND range from mild cognitive impairment to severe to neurological dementia, and the possibility of HIV-1 concurrent HAND is high, about 50% of HIV patients will show cognitive impairment, which seriously affects Patient mental health, motor function, learning and executive function. Relevant documents show that the occurrence of HAND symptoms is closely related to a high concentration of plasma viral load. Although highly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P25/28A61P31/18A61P29/00
CPCA61K31/439A61P25/28A61P31/18A61P29/00
Inventor 曹虹高雪锋龚泽龙
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com